Sanofi, AstraZeneca win EMA support for RSV drug in babies

The European Union’s drug regulator has recommended approval of AstraZeneca and Sanofi’s Beyfortus to prevent respiratory syncytial virus infection in newborns and babies, the companies said Friday. The antibody drug would be the first to be used broadly in those children.